Meta-analysis of the effects of SGLT2i on kidney outcomes10' education - June 19, 2023 - Natalie Staplin, PhD - Oxford, UK
Video navigation menu
- Aims of the meta analysis 00:29
- Results on kidney disease progression 01:42
- Results on acute kidney injury 03:12
- Results on CV death or hospitalization for heart failure 03:25
- Safety outcomes 03:43
- Conclusions 06:14
What was the main conclusion of this meta-analysis?
- A. SGLT2i reduce the risk of kidney disease progression and acute kidney injury in patients with diabetic kidney disease, but not in patients with glomerular disease or hypertensive kidney disease.
- B. SGLT2i reduce the risk of kidney disease progression, but not of acute kidney injury, irrespective of diabetes status
- C. SGLT2i reduce the risk of kidney disease progression and acute kidney injury in patients with T2DM, but not in patients without diabetes.
- D. SGLT2i reduce the risk of kidney disease progression and acute kidney injury irrespective of diabetes status.
Natalie Staplin was discussant at the EBAC-accredited symposium "Sharing international experience in CKD & SGLT2i: How to identify the right patient at the right moment?" held during the WCN 2023 in Bangkok, Thailand.
Natalie Staplin, PhD is an associate professor and a senior statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit (CTSU) at the University of Oxford in the UK.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Boehringer Ingelheim and Lilly Alliance.